Search

CPG 10101

CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. … It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.

Ivarmacitinib

While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis … Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions.

Pexelizumab

Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.

Posizolid

In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though … Posizolid (AZD2563) is an oxazolidinone antibiotic.

Mosedipimod

Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.

1alpha,24S-Dihydroxyvitamin D2

It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity. … LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol.

Parecoxib

It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. … Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union.

Declopramide

MDL72527

AT-301

AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine